Patients who are unable to swallow whole tablets are not eligible
Patients who are unable to swallow intact tablets are not eligible
Patients who are unable to swallow whole tablets are not eligible
Inability to swallow intact tablets
Inability to swallow intact tablets
Participant is unable to swallow or absorb oral tablets.
Patients who are unable to swallow tablets or liquid are not eligible.
The participant is unable to swallow tablets that are whole (do not crush or chew or administer via nasogastric [NG]-tube)
Unable or unwilling to swallow tablets as per dosing schedule
Subjects that cannot swallow tablets.
Subject is unable to swallow or absorb oral tablets normally
Unable or unwilling to swallow tablets or capsules
Patients who are unable to swallow erlotinib tablets are not eligible
Patients who are unable to swallow tablets or have a gastrointestinal disease that could hinder the absorption of enzalutamide.
Unable to swallow tablets.
Inability to swallow intact tablets
Unable or unwilling to swallow tablets or capsules
Inability to swallow intact tablets
Inability to swallow intact tablets
Unable or unwilling to swallow tablets
The subject is unable to swallow tablets
Unable or unwilling to swallow tablets
The subject is unable to swallow tablets
Subject is unable to swallow or absorb oral tablets normally
Unable to swallow tablets
Patients who cannot swallow whole tablets (i.e. medication tablets)
Unwilling or unable to swallow tablets BID
The subject is unable to swallow tablets
The subject is unable to swallow tablets
Allergy to valacyclovir or unable to take oral tablets
The subject is unable to swallow tablets
The subject is unable to swallow capsules or tablets
Unable or unwilling to swallow tablets BID
Unable or unwilling to swallow tablets
Unable to swallow tablets
The subject is unable to swallow tablets
Any condition causing an inability to swallow tablets.
The subject is unable to swallow tablets
Inability to swallow tablets
The subject is unable to swallow tablets
Inability to swallow tablets
Inability to swallow tablets or use of a feeding tube
Patients who are unable or unwilling to swallow tablets
Participant is unable or unwilling to swallow tablets
The subject is unable to swallow tablets
The subject is unable to swallow capsules tablets
The participant is unable to swallow capsules or tablets
Patients who are unable to swallow tablets
The subject is unable to swallow tablets
The subject is unable to swallow tablets
Subject is unable to swallow capsules or tablets
Unable or unwilling to swallow BBI608, BBI503, or sorafenib capsules or tablets
The subject is unable to swallow tablets
The subject is unable to swallow tablets
Inability to swallow tablets for everolimus arm
Inability to swallow tablets
Inability to swallow tablets
Unable or unwilling to swallow napabucasin capsules daily.
Patients must be able to swallow capsules
Patients unable to swallow capsules whole are not eligible; nasogastric or gastric (G) tube administration is not allowed
Patients must be able to swallow whole capsules
Patients must be able to swallow intact capsules
Patients must be able to swallow intact capsules
Able to swallow capsules
Inability to swallow capsules or known gastrointestinal malabsorption
Able to swallow ribociclib capsules
Patient must be able to swallow capsules
Able to swallow capsules
Able to swallow capsules
The subject is unable to swallow capsules.
Inability to swallow capsules
Inability to swallow gelatin capsules, or any medical condition that interferes with normal gastrointestinal absorption
Patients must be able to swallow capsules; nasogastric or gastrostomy feeding (G) tube administration is not allowed
Unable or unwilling to swallow napabucasin capsules daily.
Inability to swallow capsules, since capsules cannot be crushed or broken
Patients must be able to swallow capsules
Patient must be able to swallow capsules
Are able to swallow capsules
Patients must be able to swallow intact capsules
Patients must be able to swallow capsules
Are able to swallow capsules.
Able to swallow intact capsules
Inability to swallow capsules, since capsules cannot be crushed or broken
The subject is unable to swallow capsules
Ability to swallow capsules unless enrolled in Part E
Part E: Any patient unable to swallow capsules who otherwise meet all other eligibility criteria for Part A (expansion) B, C or D
Patients must be able to swallow whole capsules; nasogastric or gastrointestinal (G)-tube administration is not allowed
Able to swallow capsules
Patients must be able to swallow AZD1775 capsules
Ability to swallow and retain capsules.
Ability to swallow capsules
Inability to swallow capsules, since capsules cannot be crushed or broken
PART 2 GROUP 1 INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsules
PART 2 GROUP 2A INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsules
PART 2 GROUP 3 INCLUSION CRITERIA: Subjects taking capsule formulations must be able to swallow capsules
Patients must be able to swallow intact capsules whole
Patient must be able to swallow capsules
Inability or unwillingness to swallow capsules
Unable to swallow capsules
Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption; patients must be able to swallow capsules
Patient must be able to swallow capsules
Patients who are unable to swallow oral gel capsules are not eligible
Able to swallow capsules, with no surgical or anatomic condition that will preclude the patient from swallowing and absorbing oral medications
Participants must be able to swallow capsules
Able to swallow capsules whole (pomalidomide capsules cannot be crushed, dissolved or broken)
Patients must be able to swallow whole capsules
Patients must be able to swallow capsules
Patient must be able to swallow capsules
Inability to swallow lenalidomide capsules whole; capsules of 13-isotretinoin may be opened
Patients must be able to swallow capsules
Must be able to swallow ribociclib capsules
Must be able to swallow capsules and have no evidence of gastrointestinal (GI) tract abnormality that would alter the absorption of oral medications
Patients must be able to swallow capsules whole
PHASE II: Patients must be able to swallow capsules whole
Known inability to swallow capsules
Patients must be able to swallow whole capsules
Patients must be able to swallow capsules whole
Part C: Patients must be able to swallow intact capsules
Patients unable to swallow whole capsules
Able to swallow whole capsules
Patients taking the capsule formulation must be able to swallow capsules; feeding tube administration is allowed for patients receiving the oral solution (OS)
are able to swallow capsules
Patients must be able to swallow whole capsules
Inability to swallow capsules.
Patients must be able to swallow whole capsules
Subject is able to swallow capsules
Unable or unwilling to swallow BBI608 and/or BBI503 capsules daily
Unable or unwilling to swallow BBI608 capsules daily.
Must be able to swallow lenalidomide capsules
Unable or unwilling to swallow BBI608 capsules daily
Are able to swallow capsules
Unable to swallow capsules
Patients must be able to swallow capsules
Inability to swallow capsules
Patients must be able to swallow whole capsules
Inability to swallow capsules.
Unable or unwilling to swallow BBI608 capsules daily.
Able to swallow capsules
Unable or unwilling to swallow BBI503 capsules daily
Unable or unwilling to swallow BBI608 capsules daily.
Patients who cannot swallow capsules
Patients must be able to swallow intact capsules
Inability to swallow capsules or known gastrointestinal malabsorption
Ability to swallow oral capsules
Are able to swallow capsules
Unable or unwilling to swallow the complete daily dose of ARQ 087 capsules
Patients must be able to swallow the vorinostat capsules or have a feeding tube to allow for drug suspension
Inability to swallow the HKI-272 capsules
Able to swallow capsules
Able to swallow capsules
Inability to swallow capsules
Patients must be able to swallow whole capsules; capsules must not be crushed or chewed; capsules must not be opened
RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patient must be able to swallow capsules whole
NON-PROGRESSED DIPG (STRATUM 2): Patient must be able to swallow capsules whole
Inability to swallow oral capsules
Inability or unwillingness to swallow capsules
Able to swallow capsules and maintain adequate hydration
Patients will be excluded if they are unable to swallow capsules whole.
Must be able to swallow whole capsules
Unable or unwilling to swallow BBI608/placebo capsules daily.
Patients must be able to swallow capsules
Inability or unwillingness to swallow capsules
Patients must be able to swallow whole capsules
PHASE I: >= 3 years and =< 18 years of age at the time of study enrollment, if able to swallow whole capsules
Inability to swallow capsules, since capsules cannot be crushed or broken
Patients must be able to swallow capsules whole; nasogastric or gastrostomy (G) tube administration is not allowed
Able to swallow whole capsules
Patients must be able to swallow capsules
Subject is able to swallow enzalutamide capsules and comply with study requirements.
Patients must be able to swallow either intact capsules or mini-tabs without chewing
Patient must have the ability to swallow multiple capsules
Able to swallow capsules
Able to swallow oral capsules without difficulty.
Able to swallow capsules
Patient must be able to swallow capsules (phase III only)
Inability or unwillingness to swallow capsules
Patients must be able to swallow whole capsules
Unable or unwilling to swallow BBI608 capsules daily
Patients must be able to swallow tablets whole
Patients must be able to swallow tablets or capsules; a patient with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible
Patients must be able to swallow tablets
Patients must be able to swallow tablets
Patients must be able to swallow intact tablets
Patients must be able to swallow intact tablets
Patients must be able to swallow intact tablets
Patients must be able to swallow intact tablets
Patients must be able to swallow tablets
Participants must be able to swallow ribociclib capsules or tablets
Must be able to swallow ribociclib and everolimus capsules/tablets
Must be able to swallow LEE011 and everolimus capsules/tablets
Patients must be able to swallow tablets (or applesauce, if part of bioavailability \crushed\ six patient cohort)
Able to swallow tablets.
Patients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy tube (G-tube) administration is not allowed
Patients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy tube (G-tube) administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed
Participant must be able to swallow tablets or capsules. A participant with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible.
Patients must be able to swallow intact tablets
Patients who are not able to swallow intact tablets are not eligible
Has an inability to swallow tablets or capsules
Able to swallow bicalutamide and ribociclib capsules/tablets.
Be able to swallow tablets.
Are able to swallow capsules and tablets.
Patients must be able to swallow intact tablets; patients who cannot swallow intact tablets are not eligible
Able to swallow the study drugs whole as tablets
Patients must be able to swallow whole tablets
CAPMATINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
CERITINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
REGORAFENIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
ENTRECTINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules
Patient has a condition that would prevent him or her from being able to swallow Toca FC tablets or absorb flucytosine.
Inability to swallow tablets or capsules
Part E: Are able to swallow capsules or tablets
The subject must be able to swallow tablets, or receive tablets crushed and/or dispensed in water via nasogastric or orogastric tube.
Patients must be able to swallow tablets and have no significant impairment in gastrointestinal absorption
Patients who are not able to swallow capsules or tablets
Must be able to swallow ribociclib and tamoxifen capsules/tablets
Patients must be able to swallow tablets whole
Patients must be able to swallow whole tablets or capsules; nasogastric or gastrostomy (G)-tube administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed
Patients must be able to swallow capsules/tablets
Patients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed
For subjects to be enrolled in Cohort 4: Able to swallow and retain orally administered tablets
Are able to swallow capsules and tablets.
Must be able to swallow ribociclib / placebo capsules/tablets
Inability to swallow tablets or capsules
Able to swallow tablets
Patients must be willing and able to swallow oral tablets
Are able to swallow tablets
Patients must be able to swallow tablets
Patients with an inability to swallow tablets or capsules
Are able to swallow capsules or tablets
Patients must be able to swallow tablets
Able to swallow tablets
Ability to swallow intact palbociclib capsules and bicalutamide tablets
Patients must be able to swallow whole tablets (for MK-2206); nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed
Patients who are not able to swallow capsules or tablets
Patients must be able to swallow whole tablets; nasogastric or gastrostomy (G) tube administration is not allowed; tablets must not be crushed or chewed
Patients must be able to swallow tablets whole, without crushing
Patients must be able to swallow whole tablets; tablets must not be crushed or chewed
Patients must be able to swallow whole tablets and capsules
Patient must be able to swallow whole tablets
Patients must be able to swallow tablets
Patients must be able to swallow tablets
Must be able to swallow tablets and capsules
GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients must be able to swallow intact capsules/tablets, unless otherwise specified in the subprotocol to which they are assigned
Subjects must be able to swallow capsules/tablets
Patients must be able to swallow whole tablets or capsules; nasogastric or g-tube administration is not allowed; any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed
